Authors
Latest:
Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 ScoreAbstract: Pancreatic neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms. They can be functioning tumors with secretion of a variety of peptide hormones, or nonfunctioning tumors with metastases to the liver at the time of diagnosis. Well-differentiated tumors tend to be slow-growing and characterized by low tumor mutational burden (TMB) and lower propensity to express PD-L1. Hypercalcemia due to malignancy can occur in about 20% to 30% of patients with cancer. The secretion of parathyroid hormone–related protein (PTH-rP) is among the causes of malignant hypercalcemia and has seldom been associated with hypercalcemia of NETs. Although the therapeutic landscape for neuroendocrine neoplasms has evolved substantially over the past decade, the role of immunotherapy has not yet been completely explored in this group of patients. We present a rare case of a metastatic pancreatic NET with high TMB, high PD-L1 tumor proportion score, and high PTH-rP–related hypercalcemia.
Latest:
Psycho-Oncology and the Relevance of a Biopsychosocial Screening ProgramRoutine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.
Latest:
Conor E. Steuer, MD, on Smoking Cessation Habits in Patients with Early-Stage NSCLC Enrolling on Clinical TrialsCancerNetwork® sat down with Conor E. Steuer, MD, to discuss a recently published prospective study which found a high rate of smoking reduction and cessation in patients with non–small cell lung cancer.
Latest:
Matthew Allaway, DO, Discusses Transperineal Biopsy Approach for Prostate CancerMatthew Allaway, DO, detailed benefits of using an emerging transperineal biopsy approach to identify prostate cancer in hard to access areas of a patient’s prostate.
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Ovarian Function Suppression May Benefit Select Breast Cancer PopulationsPatients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Latest:
Advice for Clinicians Administering Bispecifics to Patients With R/R MMDrs Costello and Pianko close their discussion by sharing advice for clinicians administering bispecifics to their patients with relapsed/refractory multiple myeloma.
Latest:
Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell CancerIn recent years, first-line therapies for metastatic renal cell carcinoma (mRCC) have shifted to a combination of immune checkpoint inhibitors or a combination of antiangiogenesis tyrosine kinase inhibitors (TKIs) and immunotherapy. This has led to a need to address standard-of-care treatment in the second-line setting.
Latest:
Amit Oza, MD, MBBS, FRCPC, Discusses Optimizing Treatment With PARP Inhibitors in Advanced Ovarian CancerPARP inhibitors like rucaparib should be considered to treat all kinds of patients, including those who have deleterious mutations and HRD, according to Amit Oza, MD, MBBS, FRCPC.
Latest:
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited SettingA recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
Latest:
Clinical Perspectives: Utilizing CAR-T Therapy in R/R MMPanelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence institutional decision-making factors for their implementation.
Latest:
Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional FractionationABSTRACT Symptomatic spinal metastasis is a frequent complication of cancer that had been treated, until relatively recently, with primitive techniques to modest radiation dose levels, with a baseline assumption of limited survival and poor patient performance in that setting. In the era of targeted and personalized therapies, many patients are living longer and more functionally and are able to manage their disease on the model of chronic illness. Given these developments, an attractive option is the use of stereotactic body radiation therapy (SBRT) to deliver high biologically effective doses of radiation conformally to maximize the palliative gains of treatment. However, randomized data to guide practice are scarce. We review the extant literature and present an algorithmic approach to selecting patients with metastatic disease for palliative spinal SBRT favoring the results of available randomized studies and remaining within the safety constraints supported by evidence from randomized trials.
Latest:
A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast CancerThis study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.
Latest:
Minimally Invasive Surgery and Laparotomy Yield Similar OS in Ovarian CancerMinimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.
Latest:
Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and TherapyKhaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.
Latest:
Extreme Case of Surgical Port Metastasis in Ovarian CancerWe present the case of a 51-year-old woman with metastatic International FIGO stage IIIC ovarian cancer who had delayed her therapy after initial laparoscopy due to COVID-19 infection and presented with an extreme case of surgical port metastasis.
Latest:
Radiotherapy for Oligometastatic Non–Small Cell Lung Cancer: Past, Present, and FutureMcCall and Higgins examine local ablative therapy for oligometastatic NSCLC and implications for future treatment of the disease.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
Potential Solutions to Disparities in Stem Cell Transplant for Blood CancerResolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.
